 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.071.330 |
| Chemical and physical data | |
| Formula | C22H22ClN5O4S2 |
| Molar mass | 520.02 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Suproclone is asedative andanxiolytic drug in thecyclopyrrolone family of drugs, developed by the French pharmaceutical company Rhône-Poulenc.[1] Other cyclopyrrolone drugs includezopiclone,pagoclone andsuriclone.
Suproclone is very similar in structure to the related drugsuriclone, but little information has been published about it specifically. However it can be expected that the mechanism of action by which suproclone produces its sedative and anxiolytic effects is by modulating benzodiazepine receptors (resulting in an increased response to endogenousGABA), in a similar manner to other drugs of this class.[2][3]
The condensation between 2,3-Dihydro-1,4-dithiino[2,3-c]furan-5,7-dione [10489-75-5] (1) and 7-Chloro-1,8-naphthyridin-2-amine [15944-33-9] (2) gives PC23343647 (3). Halogenation with phosphoryl chloride leads to PC23343652 (4). Reductino with potassium borohydride afforded [53788-25-3] (5). Treatment with phenyl chloroformate [1885-14-9] (6) resulted in 2-(7-chloro-1,8-naphthyridin-2-yl)-3-phenoxycarbonyloxy-isoindolin-1-one, PC23343637 (7). Reaction with piperazine [110-85-0] (8) afforded (9). Acylation with propionyl chloride completed the synthesis of Suproclone (10).
